CD274 and non-small cell lung carcinoma: In addition, NSCLC patients with sensitive EGFR mutations were excluded in the clinical trial of KEYNOTE-024, which compared the efficacy of pembrolizumab and chemotherapy for PD-L1–positive NSCLC [49].